SCHEMBL5367612

SCHEMBL5367612

NC1CCN(NC(=O)Nc2ncc(-c3ccccc3)s2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.57
KDR P35968 2/20 0.53
UCHL1 P09936 1/20 0.53
CNR1 P21554 1/20 0.52
USP30 Q70CQ3 6/20 0.51
AURKA O14965 1/20 0.50
FLT3 P36888 1/20 0.50
GSTO1 P78417 1/20 0.50
CNR2 P34972 1/20 0.49
CCNE1 P24864 1/20 0.49
CDK2 P24941 1/20 0.49
CDK5 Q00535 1/20 0.49
SCD O00767 1/20 0.49
ACP1 P24666 1/20 0.47
CYP3A4 P08684 1/20 0.46
OTUD7B Q6GQQ9 2/20 0.45
NPY5R Q15761 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353588 0.93 MKNK1 (0.55) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5354171 0.93 MKNK1 (0.55) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5353583 0.93 MKNK1 (0.55) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5354063 0.89 MKNK1 (0.64) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5352128 0.87 USP30 (0.55) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5352138 0.87 USP30 (0.55) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5352132 0.87 USP30 (0.55) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5360700 0.84 KDR (0.55) MKNK1KDRUCHL1CNR1USP30
SCHEMBL14407987 0.84 CNR2 (0.64) MKNK1KDRUCHL1CNR1USP30
SCHEMBL5359220 0.81 MKNK1 (0.57) MKNK1KDRUCHL1CNR1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265134-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-09-04 US claimed
US-20040192926-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2004-09-30 US claimed
WO-2003015778-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-02-27 WO claimed
US-7265134-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-09-04 US disclosed
US-20040192926-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2004-09-30 US disclosed
WO-2003015778-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192926-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 MKNK1 82/4885KDR 5/4885UCHL1 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.